Acumen Pharmaceuticals presented extended results from its validated research-use plasma pTau217 assay at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2025. The data confirmed that this screening strategy performed as intended, leading to efficient screening and enrollment in the Phase 2 ALTITUDE-AD trial.
The pTau217 enrichment strategy reduced the number of amyloid PET scans or CSF procedures for potential trial participants compared to the INTERCEPT-AD trial. This efficiency eases the burden on patients, investigators, and site staff, fostering a more patient-centric clinical trial experience.
Additionally, Acumen presented posters on methods for interrogating AβO binding to human neurons, advancing Aβ selectivity measurements, and early effects of sabirnetug on synaptic biomarkers in AD. One study showed sabirnetug blocked AβO binding to synapses in an iPSC-derived neuronal model, reinforcing its mechanism of action.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.